Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Harold E Bays, Eliot A Brinton, Joseph Triscari, Erluo Chen, Darbie Maccubbin, Alexandra A MacLean, Kendra L Gibson, Rae Ann Ruck, Amy O Johnson-Levonas, Edward A O’Neill & Yale B Mitchel. (2015) Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control. Vascular Health and Risk Management 11, pages 165-172.
Read now
Read now
Rahul Yadav, Michael France, Naveed Younis, Salam Hama, Basil J Ammori, See Kwok & Handrean Soran. (2012) Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety. Expert Opinion on Pharmacotherapy 13:9, pages 1345-1362.
Read now
Read now
Rahul Yadav, See Kwok, Basil J. Ammori, Basil Issa & Handrean Soran. (2012) Safety and tolerability of extended-release niacin with laropiprant. Expert Opinion on Drug Safety 11:1, pages 151-159.
Read now
Read now
Ayman A Hussein & Stephen J Nicholls. (2010) Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. Therapeutics and Clinical Risk Management 6, pages 183-190.
Read now
Read now
Kurt Bestehorn, Wenefrieda Smolka, David Pittrow, Helmut Schulte & Gerd Assmann. (2010) Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. Current Medical Research and Opinion 26:12, pages 2833-2839.
Read now
Read now
Kai-Hang Yiu, Bernard MY Cheung & Hung-Fat Tse. (2010) A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin. Expert Opinion on Investigational Drugs 19:3, pages 437-449.
Read now
Read now
Articles from other publishers (10)
T. Rhodes, J. M. Norquist, C. McCrary Sisk, K. McQuarrie, A. Trovato, J. Liao, T. Miller, D. Maccubbin & D. J. Watson. (2013) The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy. International Journal of Clinical Practice 67:12, pages 1238-1246.
Crossref
Crossref
Venkata M. Alla, Vrinda Agrawal, Andrew DeNazareth, Syed Mohiuddin, Sudha Ravilla & Marc Rendell. (2013) A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs. Drugs 73:10, pages 1025-1054.
Crossref
Crossref
Harold BaysHilde GiezekJames M. McKenneyEdward A. O'NeillAndrew M. Tershakovec. (2012) Extended-Release Niacin/Laropiprant Effects on Lipoprotein Subfractions in Patients with Type 2 Diabetes Mellitus. Metabolic Syndrome and Related Disorders 10:4, pages 260-266.
Crossref
Crossref
Carol M. Mason & Amy L. Doneen. (2012) Niacin—A Critical Component to the Management of Atherosclerosis. Journal of Cardiovascular Nursing 27:4, pages 303-316.
Crossref
Crossref
Marc Dorais, Diana Chirovsky, Baishali Ambegaonkar, Vasilisa Sazonov, Glenn Davies, Susan Grant & Jacques LeLorier. (2010) Utilization patterns of extended-release niacin in Canada: Analysis of an administrative claims database. Canadian Journal of Cardiology 26:7, pages e229-e235.
Crossref
Crossref
M. John Chapman, Jan S. Redfern, Mark E. McGovern & Philippe Giral. (2010) Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics 126:3, pages 314-345.
Crossref
Crossref
Terry A. Jacobson. (2010) A “Hot” Topic in Dyslipidemia Management—“How to Beat a Flush”: Optimizing Niacin Tolerability to Promote Long-term Treatment Adherence and Coronary Disease Prevention. Mayo Clinic Proceedings 85:4, pages 365-379.
Crossref
Crossref
James McKenney, Harold Bays, Michael Koren, Christie M. Ballantyne, John F. Paolini, Yale Mitchel, Abigaile Betteridge, Olga Kuznetsova, Aditi Sapre, Christine McCrary Sisk & Darbie Maccubbin. (2010) Safety of extended-release niacin/laropiprant in patients with dyslipidemia. Journal of Clinical Lipidology 4:2, pages 105-112.e1.
Crossref
Crossref
Rajesh Peter & Alan Rees. (2009) Diabetes and cardiovascular disease: new perspectives. Current Opinion in Lipidology 20:2, pages 145-146.
Crossref
Crossref
John F. Paolini, Harold E. Bays, Christie M. Ballantyne, Michael Davidson, Richard Pasternak, Darbie Maccubbin, Josephine M. Norquist, Eseng Lai, M. Gerard Waters, Olga Kuznetsova, Christine McCrary Sisk & Yale B. Mitchel. (2008) Extended-Release Niacin/Laropiprant: Reducing Niacin-Induced Flushing to Better Realize the Benefit of Niacin in Improving Cardiovascular Risk Factors. Cardiology Clinics 26:4, pages 547-560.
Crossref
Crossref